论文部分内容阅读
本文报告肾综合征出血热纯化灭活疫苗在浙江省高发疫区大面积人群接种后的安全性、血清学和流行病学近期防病效果。本次共接种１０４６０人，全程接种者占９７．３０％；对照１６１５９人。全程接种后两周荧光抗体阳转率为９８．５５％（６８／６９），中和抗体阳转率为４４．８３％，几何平均滴度分别为６９．３６和４．４４。经一个流行期观察，接种组无发病；对照组发病１２例，发病率为７４．２６／１０万，人群近期保护率达１００％。人群接种后局部和全身反应较明显，注射局部疼痛感达１００％，但均未发生异常反应（包括隐性感染者）。预测疫苗接种后当年发病数减少了３３例，取得一定的经济和社会效益。
This article reports the safety, serology and epidemiology of anti-haemorrhagic fever inactivated vaccine against hemorrhagic fever with renal syndrome after vaccination in a large area in Zhejiang Province. The total inoculation of 10460 people, the entire vaccination accounted for 97.30%; control 16,159 people. Two weeks after inoculation, the positive rate of fluorescent antibody was 98.55% (68/69), the neutralization antibody positive rate was 44.83%, and the geometric mean titers were 69.36 and 4.44 respectively. After one epidemic period observation, the inoculation group had no incidence; in the control group, 12 cases were found, the incidence rate was 74.26 / 100000, the recent population protection rate was 100%. Local and systemic reactions were more pronounced after inoculation in humans, with localized pain sensations of up to 100% after injection, but no abnormal reactions (including those with latent infection) occurred. The incidence of vaccination in the year after the vaccination was reduced by 33 cases and achieved certain economic and social benefits.